Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) Director John Houston sold 35,297 shares of the firm's stock in a transaction on Friday, February 27th. The stock was sold at an average price of $13.21, for a total value of $466,273.37. Following the completion of the transaction, the director directly owned 1,122,183 shares of the company's stock, valued at $14,824,037.43. The trade was a 3.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Arvinas Stock Performance
NASDAQ:ARVN opened at $13.39 on Tuesday. The business's fifty day moving average is $12.50 and its 200 day moving average is $10.69. The firm has a market cap of $856.42 million, a price-to-earnings ratio of -10.46 and a beta of 1.87. Arvinas, Inc. has a 52-week low of $5.90 and a 52-week high of $18.93.
Arvinas (NASDAQ:ARVN - Get Free Report) last issued its earnings results on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.55). Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The company had revenue of $9.50 million during the quarter, compared to the consensus estimate of $37.26 million. During the same quarter in the prior year, the business earned ($0.63) EPS. The firm's revenue for the quarter was down 84.0% compared to the same quarter last year. Equities analysts predict that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.
Institutional Trading of Arvinas
Hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. raised its stake in shares of Arvinas by 26.9% during the fourth quarter. Invesco Ltd. now owns 302,100 shares of the company's stock worth $3,583,000 after acquiring an additional 64,044 shares in the last quarter. Corient Private Wealth LLC bought a new position in shares of Arvinas during the 4th quarter valued at $127,000. State of Tennessee Department of Treasury purchased a new position in Arvinas in the 4th quarter worth $323,000. Ikarian Capital LLC lifted its stake in Arvinas by 58.3% in the fourth quarter. Ikarian Capital LLC now owns 358,257 shares of the company's stock worth $4,249,000 after purchasing an additional 132,000 shares during the last quarter. Finally, Voloridge Investment Management LLC bought a new stake in Arvinas in the fourth quarter worth $1,079,000. Hedge funds and other institutional investors own 95.19% of the company's stock.
Wall Street Analysts Forecast Growth
ARVN has been the topic of several recent analyst reports. Wells Fargo & Company lowered their target price on shares of Arvinas from $16.00 to $15.00 and set an "overweight" rating on the stock in a research note on Thursday, November 6th. Piper Sandler reiterated an "overweight" rating and issued a $20.00 price objective (up from $16.00) on shares of Arvinas in a research report on Wednesday, February 25th. Wall Street Zen lowered Arvinas from a "hold" rating to a "sell" rating in a research note on Monday. Wedbush upped their target price on Arvinas from $9.00 to $11.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 24th. Finally, Citigroup upgraded Arvinas from a "neutral" rating to a "buy" rating and lifted their price target for the company from $10.00 to $15.00 in a research report on Tuesday, January 6th. Ten investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Arvinas presently has a consensus rating of "Hold" and an average price target of $13.47.
Read Our Latest Stock Analysis on Arvinas
About Arvinas
(
Get Free Report)
Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.
The company's most advanced clinical candidates address hormone-driven cancers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
